Real‐world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study-Reference-Cited by-同舟云学术

Real‐world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study

Published:2024-06-19 Issue: Volume: Page:
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Aust J Dermatology

Author:

Mansilla‐Polo Miguel¹²^ORCID,Pons‐Benavent Martí³^ORCID,Fernández‐Crehuet Pablo⁴,Vilarrasa Eva⁵,Albanell‐Fernández Cristina⁶^ORCID,Morales‐Tedone Enrico⁶,Rausell‐Félix Francisca⁶,Alcalá‐García Rebeca⁷,Matellanes‐Palacios María⁷^ORCID,Martín‐Ezquerra Gemma⁸,Alfageme Fernando⁹,Ciudad‐Blanco Cristina¹⁰,López‐Villaescusa María Teresa¹¹,Garbayo‐Salmons Patricia¹²^ORCID,Martorell Antonio¹³,Escutia‐Muñoz Begoña¹²,Navarro‐Blanco Fernando¹²,Martín‐Torregrosa Daniel¹²,Cuenca‐Barrales Carlos¹⁴^ORCID,Molina‐Leyva Alejandro¹⁴,Botella‐Estrada Rafael¹²¹⁵

Affiliation:

1. Departamento de Dermatología Hospital Universitario y Politécnico La Fe Valencia Spain

2. Instituto de Investigación Sanitaria (IIS) La Fe Valencia Spain

3. Departamento de Dermatología Hospital Virgen de los Lirios Alicante Spain

4. Departamento de Dermatología Hospital Reina Sofía Córdoba Spain

5. Departamento de Dermatología Hospital de la Santa Creu i Sant Pau Barcelona Spain

6. Departamento de Dermatología Hospital Clínico Universitario Valencia Spain

7. Departamento de Dermatología Hospital de Sagunto Valencia Spain

8. Departamento de Dermatología Hospital del Mar Barcelona Spain

9. Departamento de Dermatología Hospital Universitario Puerta de Hierro Madrid Spain

10. Departamento de Dermatología Hospital Universitario Gregorio Marañón Madrid Spain

11. Departamento de Dermatología Complejo Hospitalario Universitario de Albacete Albacete Spain

12. Departamento de Dermatología Hospital Parc Taulí de Sabadell Barcelona Spain

13. Departamento de Dermatología Hospital de Manises Valencia Spain

14. Departamento de Dermatología Hospital Universitario Virgen de las Nieves Granada Spain

15. Facultad de Medicina Universitat de València Valencia Spain

Abstract

AbstractIn this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient‐reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS‐PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well‐tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real‐world clinical practice for treating HS.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.14339

Reference7 articles.

1. Hidradenitis suppurativa

2. Bimekizumab Efficacy by Prior Biologic Treatment in Patients with Moderate to Severe Hidradenitis Suppurativa: 48-Week Pooled Data from the Randomized, Double-Blind, Placebo-Controlled, Multicenter BE HEARD I and II Phase 3 Trials

3. Bimekizumab Impact on Pain in Moderate to Severe Hidradenitis Suppurativa: Week 16 Results from BE HEARD I & II

4. ZouboulisCCG FormanS WeismanJ SzepietowskiJC PrensEP FujitaH et al.Bimekizumab efficacy and safety in patients with moderate to severe hidradenitis suppurativa: Analysis of pooled data from BE HEARD I & II phase 3 randomised double‐blind placebo‐controlled multicentrestudies. EADV Congress2023.

5. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa